This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Multiplex Biomarker Imaging Market

Market Insights on Multiplex Biomarker Imaging covering sales outlook, demand forecast & up-to-date key trends

Multiplex Biomarker Imaging Market by Component Type (Instruments, Software and Services), Imaging Technique (Immunohistochemistry (IHC) Assay, Fluorescent in Situ Hybridization (FISH) Assay and Tissue Microarray (TMA) Assay) & Region - Forecast 2022 - 2029

Multiplex Biomarker Imaging Market Snapshot

[280 Pages Report] The global Multiplex Biomarker Imaging Market was valued at US$ 422.1 Mn in 2021 and is expected to reach US$ 1,041.7 Mn by 2029, finds Future Market Insights (FMI) in a recent market survey.

Data Points

Market Insights

Market Value 2022

USD 475.2 Mn

Market Value 2029

USD 1,041.7 Mn

CAGR 2022-2029

11.9%

Key Players

The key players are PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH (Danaher Corporation), Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary), Aushon BioSystems Ltd., MicroConstants, Inc., and ToposNomos Ltd. (TNL)

Share of Top 5 Countries           

70.7%

The growing prevalence of tumor and cancer among population around the world and increasing demand for more effective treatment and medicine for different types of cancer are primary factors fueling the multiplex biomarker imaging market.

In addition, the growing adoption of personalized medicine is expected to drive the growth of multiplex biomarker imaging market. Moreover, availability of technologically advanced instruments is likely to add to the market development.

Multiplex biomarker imaging market holds nearly 1.6% market value share of the US$ 31 Bn biomarkers market in 2021. An increase in production base of multispectral imaging devices that could provide multiplexing is expected to fuel the revenue growth of device manufacturers.

Leading manufacturers of multiplex biomarker imaging are also focusing on collaborations with laboratories and biopharmaceutical companies in order to expand sales presence.  

Driven by this, sales of multiplex biomarker imaging are expected to rise at an 11.9% CAGR through 2029.

2012-2021 Multiplex Biomarker Imaging Market Demand Outlook Compared to 2022-2029 Forecast

Sales of multiplex biomarker imaging grew at a CAGR of 13.5% between 2012 and 2021.

The multiplex biomarker imaging market is expected to show rapid growth owing to increasing prevalence of chronic diseases, rising adoption of personalized medicine, and a broad range of benefits of multiplex imaging over traditional imaging.

In addition, high prevalence of cardiac and cancer problems, advancements of biomarkers and increased application are the key factors contributing to the market development. The surge in cancer cases worldwide has led to increase in use of biomarkers with development in technology. As per the WCRF (World Cancer Research Fund International), about 18 million cases were there across the world in 2020. Also, the global burden of cancer cure and prevention is of the chief concern for the pharmaceutical and governments companies.

Considering this, FMI expects the global multiplex biomarker imaging market to grow at a CAGR of 11.9% through 2029.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Factors Are Restraining Demand for Multiplex Biomarker Imaging?

The complexity of the process and unclear regulatory guidance on the commercial sale of digital pathology imaging products are anticipated to hamper the multiplex biomarker imaging market growth. There is unclear regulatory control on commercial diagnostic use of whole slide imaging (WSI) products comprising multiplex biomarker imaging systems.

In addition, lack of awareness regarding multiplex biomarker imaging and cloud-enabled technologies, especially in developing countries, is restraining growth of the market. Also, the high cost of the multiplex biomarker imaging devices is prohibiting the adoption of these devices in research laboratories dealing with cancer research.

What is the Impact of the COVID-19 Crisis on the Multiplex Biomarker Imaging Market?

The coronavirus continues its march around the globe, disrupting nearly every business around the world. The market observed a huge slowdown in its growth due to the spread of Covid-19 pandemic worldwide.

As a result of pandemic related lockdowns in different countries and disruptions in the supply chain of medical equipment, the multiplex biomarker imaging market witnessed a drop during the lockdown period.

Also, the manufacturers encountered several operational challenges that initially hampered their business activities during the lockdown. Ultimately, with the relaxing of the lockdown and exceptional demand of the diagnosis, the sales of the multiple companies have grown positively. But, in the case of the multiplex biomarker imaging market, as these are playing a vital role in the development of therapies for chronic diseases, where pharmaceutical and government industries is expected to spend a lot, the market is expected to boost during the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-wise Insights

What Makes the U.S. a Large Market for Multiplex Biomarker Imaging?

The U.S. is estimated to account for around 91.3% of the North America multiplex biomarker imaging market in 2022.  

The growing prevalence of chronic diseases, like cancer, rising demand for personalized and targeted medicine, favorable government initiatives, and growing aging population are the key factors contributing to the growth of the market in U.S. The development can also be due to the availability of sophisticated diagnostics laboratories and great adoption rate of novel assay technologies. In addition, nearly every pharmaceutical manufacturer has been developing molecular biomarker products, either through different ventures or through partnerships.

Why is Germany Considered a Lucrative Multiplex Biomarker Imaging Market?

Germany is estimated to account for 20.2% of the Europe multiplex biomarker imaging market in Europe in 2022.

The growth of the market in Germany is because of the growing demand for automated equipment and commercialization of multipurpose instruments with cloud-enabled technologies in many labs and research facilities. In addition, growing cancer research funding by biotech and pharmaceutical companies is leading to increased biomarker discovery which is contributing to the market development. Also, growing prevalence of cancer is resulting into greater adoption of these biomarkers for early diagnosis which is increasing the demand for the market in Germany.

What are the Factors Fueling the Demand for Multiplex Biomarker Imaging in Japan?

The multiplex biomarker imaging market in Japan is estimated to be worth US$ 21.8 Mn in 2022 in the global market.

The major factors responsible for the development of the market in Japan are existence of a huge patient pool, rising focus on efficient and rapid diagnostics because of rising incidence of chronic diseases, presence of manufacturers in Japan and increasing investment to improve robust healthcare facilities.

Moreover, rising awareness concerning the significance of biomarkers in clinical diagnostics, developments in drug discovery and manufacturing processes, and growing clinical studies to understand the role of biomarkers in prognosis and diagnosis of complex diseases is expected to have a favorable effect on growth of the market.

How will the Multiplex Biomarker Imaging Market Expand across India?

Demand for multiplex biomarker imaging in India is expected to rise at around 6.6% CAGR over the forecast period.

Increased focus on cancer research and increased demand for testing of non-small cell lung cancer are primary factors leading to the growth of the market in India. There is increased focus on cancer research in India. Also, there is increased awareness for better diagnosis and focus on establishment of better research facilities in the country. Thus, increased access to better healthcare and diagnostic infrastructure and establishment of translational laboratories are factors fueling the demand for better imaging systems.

Category-wise Insights

Demand for Instruments to continue gaining Traction

By component type, instruments segment is anticipated to hold the maximum share of 73.9% in 2022, expanding at rate of nearly 11.8% during the forecast period.

The advantages offered by instruments like reliability, high image quality, and speed for entire slide imaging are encouraging the companies towards these instrument. Moreover, assessable pathology imaging systems, even though in their nascent stage, are adding to the potential sales forecasts for market players. Growing funding to develop advanced clinical and research laboratories has led to an increase in purchase of these instruments, which is anticipated to contribute to development of the segment.

Why Immunohistochemistry (IHC) Assay will hold the most of the market share?

By imaging technique, Immunohistochemistry (IHC) Assay will lead the market and is projected to account for 66.5% of the total market revenue share in 2022.

IHC is a histological method for identifying and localizing proteins in tissue specimens. This assay identifies some biomarkers such as oxidative stress, inflammation, tumors, and other diseases which assist in the diagnosis of complex diseases such as cancer using advanced methods. Thus, considering efficiency in regards to accuracy and processing time during detection of target proteins in tissue specimens, immunohistochemistry (IHC) assays is expected to lead the market over the forecast period.

Which application is most sought-after over the forecast period?

By application, research will be the most sought-after application and is projected to account for 86.5% of the total market revenue share in 2022.

Biomarkers are vital in medicine and play a significant role in research activities such as drug discovery and development. These can determine drug efficacy at a rapid pace in comparison to traditional clinical endpoints and is expected to fuel the product development for serious disease indications. Thus, good success rates of biomarkers in drug discovery is increasing its application in research, which in turn is leading to segment growth.

Why Translational Laboratories projected maximum growth in the Multiplex Biomarker Imaging Market?

By end user, translational laboratories segment is anticipated to hold the maximum share of 47.8% in 2022, expanding at rapid rate of 15.3% CAGR during the forecast period.

Multiplex Biomarker Imaging is utilized in translation laboratories as they offer a high-resolution methodology for creating immunohistochemistry images and precise scores of biomarkers. This method also aids to speed up the procedure by decreasing the amount of slides needed per marker, which leads to time-saving while performing analysis.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competitive Landscape

Companies operating in the Multiplex Biomarker Imaging market are moderately competitive by nature, with a presence of few players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:

  • In April 2021, Abcam, formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.

Scope of the Report

Attribute

Details

Forecast Period

2012-2021

Historical Data Available for

2022-2029

Market Analysis

USD Million for Value and Units for Volume

Key Countries Covered

US, Canada, Brazil, Mexico, Germany, Argentina, U.K., Germany, France, Italy, Spain, Nordic, Benelux, Russia, Poland, China, Japan, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa

Key Segments Covered

Component Type, Imaging Technique, Application, End User and Region

Key Companies Profiled

  • PerkinElmer Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Abcam plc.
  • Merck KGaA
  • Illumina Inc.
  • Leica Biosystems Nussloch GmbH (Danaher Corporation)
  • Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary)
  • Aushon BioSystems Ltd.
  • MicroConstants, Inc.
  • ToposNomos Ltd. (TNL)

Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Multiplex Biomarker Imaging Market by Category

By Component Type:

  • Instruments
    • Quantitative Pathology Imaging System
    • Immunofluorescence
    • Multispectral Imaging System
    • Toponome Imaging System
  • Software
  • Services
    • Installation and Integration Services
    • Maintenance Services

By Imaging Technique:

  • Immunohistochemistry (IHC) Assay
  • Fluorescent In Situ Hybridization (FISH) Assay
  • Tissue Microarray (TMA) Assay

By Application:

  • Research
  • Clinical Diagnostics

By End User:

  • Translation Laboratories
  • Biopharmaceutical Companies
  • Academic Institutes

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • Middle East and Africa

Frequently Asked Questions

The global multiplex biomarker imaging market is worth US$ 422.1 Mn in 2021 and is set to expand 2.2X over the forecasted years owing to the rising cancer research and growing demand for personalized medicine.

The sales of Multiplex Biomarker Imaging in the market have grown at a CAGR of nearly 13.5% between 2012 and 2021. Increasing prevalence of chronic diseases and development in imaging assays is responsible for growth over the years.

The multiplex biomarker imaging market is expected to reach US$ 1,041.7 Mn by the end of 2029 with sales revenue expected to register CAGR of 11.9% over the forecast period.

North America currently holds the largest market share of around 57.0% in 2022 in the multiplex biomarker imaging market globally with U.S. being the leading contributor with a market value over US$ 247.3 Mn in North America market in 2022.

Demand of multiplex biomarker imaging market is expected to register growth in Western Europe at rate of 11.3% CAGR during the forecast period.

The Multiplex Biomarker Imaging in Japan is likely to observe growth with an impressive CAGR of 11.7% during the forecast period. The major factors responsible for the development of the market in Japan are existence of a huge patient pool, rising focus on efficient and rapid diagnostics because of rising incidence of chronic diseases, presence of manufacturers in Japan and increasing investment to improve robust healthcare facilities.

Growing adoption of IHC processes in immunofluorescence imaging and rising demand for large data set analysis are key trends driving sales of multiplex biomarker imaging market across the globe.

China’s Multiplex Biomarker Imaging market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 12.0% CAGR during the forecast period. India market expected to exhibit healthy growth of 6.6% CAGR during the forecast period.

U.S., Germany, Canada, Japan and U.K. are the top 5 countries that are driving the demand for multiplex biomarker imaging market.

Leading companies of multiplex biomarker imaging are PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH (Danaher Corporation), Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary), Aushon BioSystems Ltd., MicroConstants, Inc., and ToposNomos Ltd. (TNL)

Table of Content

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FMI Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Taxonomy

    2.2. Market Definition

3. Market View Point

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis

    3.3. Trends

    3.4. Restrains    

    3.5. Pricing Analysis 2021 and 2029

4. North America Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    4.1. Introduction

    4.2. Regional Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Trends

    4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021

        4.3.1. U.S.

        4.3.2. Canada

    4.4. Market Size (US$ Mn) Forecast By Country, 2022–2029

        4.4.1. U.S.

        4.4.2. Canada

    4.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        4.5.1. Instruments

            4.5.1.1. Quantitative Pathology Imaging System

            4.5.1.2. Immunofluorescence Slide Scanner

            4.5.1.3. Multispectral Imaging Systems

            4.5.1.4. Toponome imaging System

        4.5.2. Software

        4.5.3. Services

            4.5.3.1. Installation & Integration Services

            4.5.3.2. Maintenance Service

    4.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        4.6.1. Instruments

            4.6.1.1. Quantitative Pathology Imaging System

            4.6.1.2. Immunofluorescence Slide Scanner

            4.6.1.3. Multispectral Imaging Systems

            4.6.1.4. Toponome imaging System

        4.6.2. Software

        4.6.3. Services

            4.6.3.1. Installation & Integration Services

            4.6.3.2. Maintenance Service

    4.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        4.7.1. Immunohistochemistry (IHC) Assay

        4.7.2. Fluorescent In Situ Hybridization (FISH) Assay

        4.7.3. Tissue Microarray (TMA) Assay

    4.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        4.8.1. Immunohistochemistry (IHC) Assay

        4.8.2. Fluorescent In Situ Hybridization (FISH) Assay

        4.8.3. Tissue Microarray (TMA) Assay

    4.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        4.9.1. Research

        4.9.2. Clinical Diagnostics

    4.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        4.10.1. Research

        4.10.2. Clinical Diagnostics

    4.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        4.11.1. Translational Laboratories

        4.11.2. Biopharmaceutical Companies

        4.11.3. Academic Institutes

    4.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        4.12.1. Translational Laboratories

        4.12.2. Biopharmaceutical Companies

        4.12.3. Academic Institutes

    4.13. Drivers and Restraints: Impact Analysis

    4.14. Market Attractiveness Analysis

        4.14.1. By Country

        4.14.2. By Component Type

        4.14.3. By Imaging Technique

        4.14.4. Application

        4.14.5. End User

    4.15. Key Representative Market Presence (Intensity Map)

5. Latin America Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    5.1. Introduction

    5.2. Regional Market Dynamics

        5.2.1. Drivers

        5.2.2. Restraints

        5.2.3. Trends

    5.3. Historical Market Size (US$ Mn)  Analysis By Country, 2012-2021

        5.3.1. Brazil

        5.3.2. Mexico

        5.3.3. Argentina

        5.3.4. Rest of  Latin America

    5.4. Market Size (US$ Mn) Forecast By Country, 2022–2029

        5.4.1. Brazil

        5.4.2. Mexico

        5.4.3. Argentina

        5.4.4. Rest of  Latin America

    5.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        5.5.1. Instruments

            5.5.1.1. Quantitative Pathology Imaging System

            5.5.1.2. Immunofluorescence Slide Scanner

            5.5.1.3. Multispectral Imaging Systems

            5.5.1.4. Toponome imaging System

        5.5.2. Software

        5.5.3. Services

            5.5.3.1. Installation & Integration Services

            5.5.3.2. Maintenance Service

    5.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        5.6.1. Instruments

            5.6.1.1. Quantitative Pathology Imaging System

            5.6.1.2. Immunofluorescence Slide Scanner

            5.6.1.3. Multispectral Imaging Systems

            5.6.1.4. Toponome imaging System

        5.6.2. Software

        5.6.3. Services

            5.6.3.1. Installation & Integration Services

            5.6.3.2. Maintenance Service

    5.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        5.7.1. Immunohistochemistry (IHC) Assay

        5.7.2. Fluorescent In Situ Hybridization (FISH) Assay

        5.7.3. Tissue Microarray (TMA) Assay

    5.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        5.8.1. Immunohistochemistry (IHC) Assay

        5.8.2. Fluorescent In Situ Hybridization (FISH) Assay

        5.8.3. Tissue Microarray (TMA) Assay

    5.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        5.9.1. Research

        5.9.2. Clinical Diagnostics

    5.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        5.10.1. Research

        5.10.2. Clinical Diagnostics

    5.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        5.11.1. Translational Laboratories

        5.11.2. Biopharmaceutical Companies

        5.11.3. Academic Institutes

    5.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        5.12.1. Translational Laboratories

        5.12.2. Biopharmaceutical Companies

        5.12.3. Academic Institutes

    5.13. Drivers and Restraints: Impact Analysis

    5.14. Market Attractiveness Analysis

        5.14.1. By Country

        5.14.2. By Component Type

        5.14.3. By Imaging Technique

        5.14.4. Application

        5.14.5. End User

    5.15. Key Representative Market Presence (Intensity Map)

6. Western Europe Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    6.1. Introduction

    6.2. Regional Market Dynamics

        6.2.1. Drivers

        6.2.2. Restraints

        6.2.3. Trends

    6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021

        6.3.1. U.K.

        6.3.2. Germany

        6.3.3. France

        6.3.4. Italy

        6.3.5. Spain

        6.3.6. Nordics

        6.3.7. BENELUX

        6.3.8. Rest of Western Europe

    6.4. Market Size (US$ Mn) Forecast By Country, 2022–2029

        6.4.1. U.K.

        6.4.2. Germany

        6.4.3. France

        6.4.4. Italy

        6.4.5. Spain

        6.4.6. Nordics

        6.4.7. BENELUX

        6.4.8. Rest of Western Europe

    6.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        6.5.1. Instruments

            6.5.1.1. Quantitative Pathology Imaging System

            6.5.1.2. Immunofluorescence Slide Scanner

            6.5.1.3. Multispectral Imaging Systems

            6.5.1.4. Toponome imaging System

        6.5.2. Software

        6.5.3. Services

            6.5.3.1. Installation & Integration Services

            6.5.3.2. Maintenance Service

    6.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        6.6.1. Instruments

            6.6.1.1. Quantitative Pathology Imaging System

            6.6.1.2. Immunofluorescence Slide Scanner

            6.6.1.3. Multispectral Imaging Systems

            6.6.1.4. Toponome imaging System

        6.6.2. Software

        6.6.3. Services

            6.6.3.1. Installation & Integration Services

            6.6.3.2. Maintenance Service

    6.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        6.7.1. Immunohistochemistry (IHC) Assay

        6.7.2. Fluorescent In Situ Hybridization (FISH) Assay

        6.7.3. Tissue Microarray (TMA) Assay

    6.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        6.8.1. Immunohistochemistry (IHC) Assay

        6.8.2. Fluorescent In Situ Hybridization (FISH) Assay

        6.8.3. Tissue Microarray (TMA) Assay

    6.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        6.9.1. Research

        6.9.2. Clinical Diagnostics

    6.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        6.10.1. Research

        6.10.2. Clinical Diagnostics

    6.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        6.11.1. Translational Laboratories

        6.11.2. Biopharmaceutical Companies

        6.11.3. Academic Institutes

    6.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        6.12.1. Translational Laboratories

        6.12.2. Biopharmaceutical Companies

        6.12.3. Academic Institutes

    6.13. Drivers and Restraints: Impact Analysis

    6.14. Market Attractiveness Analysis

        6.14.1. By Country

        6.14.2. By Component Type

        6.14.3. By Imaging Technique

        6.14.4. Application

        6.14.5. End User

    6.15. Key Representative Market Presence (Intensity Map)

7. Eastern Europe Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    7.1. Introduction

    7.2. Historical Market Size (US$ Mn) Analysis  By Country, 2012-2021

        7.2.1. Russia

        7.2.2. Poland

        7.2.3. Rest of Eastern Europe

    7.3. Market Size (US$ Mn) Forecast By Country,2022–2029

        7.3.1. Russia

        7.3.2. Poland

        7.3.3. Rest of Eastern Europe

    7.4. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        7.4.1. Instruments

            7.4.1.1. Quantitative Pathology Imaging System

            7.4.1.2. Immunofluorescence Slide Scanner

            7.4.1.3. Multispectral Imaging Systems

            7.4.1.4. Toponome imaging System

        7.4.2. Software

        7.4.3. Services

            7.4.3.1. Installation & Integration Services

            7.4.3.2. Maintenance Service

    7.5. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        7.5.1. Instruments

            7.5.1.1. Quantitative Pathology Imaging System

            7.5.1.2. Immunofluorescence Slide Scanner

            7.5.1.3. Multispectral Imaging Systems

            7.5.1.4. Toponome imaging System

        7.5.2. Software

        7.5.3. Services

            7.5.3.1. Installation & Integration Services

            7.5.3.2. Maintenance Service

    7.6. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        7.6.1. Immunohistochemistry (IHC) Assay

        7.6.2. Fluorescent In Situ Hybridization (FISH) Assay

        7.6.3. Tissue Microarray (TMA) Assay

    7.7. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        7.7.1. Immunohistochemistry (IHC) Assay

        7.7.2. Fluorescent In Situ Hybridization (FISH) Assay

        7.7.3. Tissue Microarray (TMA) Assay

    7.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        7.8.1. Research

        7.8.2. Clinical Diagnostics

    7.9. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        7.9.1. Research

        7.9.2. Clinical Diagnostics

    7.10. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        7.10.1. Translational Laboratories

        7.10.2. Biopharmaceutical Companies

        7.10.3. Academic Institutes

    7.11. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        7.11.1. Translational Laboratories

        7.11.2. Biopharmaceutical Companies

        7.11.3. Academic Institutes

    7.12. Market Attractiveness Analysis

        7.12.1. By Country

        7.12.2. By Component Type

        7.12.3. By Imaging Technique

        7.12.4. Application

        7.12.5. End User

    7.13. Key Representative Market Presence (Intensity Map)

8. Asia-Pacific Excluding Japan (APEJ) Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    8.1. Introduction

    8.2. Regional Market Dynamics

        8.2.1. Drivers

        8.2.2. Restraints

        8.2.3. Trends

    8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021

        8.3.1. China

        8.3.2. India

        8.3.3. Australia and New Zealand

        8.3.4. ASEAN

        8.3.5. Rest of  APEJ

    8.4. Market Size (US$ Mn) Forecast By Country, 2022–2029

        8.4.1. China

        8.4.2. India

        8.4.3. Australia and New Zealand

        8.4.4. ASEAN

        8.4.5. Rest of  APEJ

    8.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        8.5.1. Instruments

            8.5.1.1. Quantitative Pathology Imaging System

            8.5.1.2. Immunofluorescence Slide Scanner

            8.5.1.3. Multispectral Imaging Systems

            8.5.1.4. Toponome imaging System

        8.5.2. Software

        8.5.3. Services

            8.5.3.1. Installation & Integration Services

            8.5.3.2. Maintenance Service

    8.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        8.6.1. Instruments

            8.6.1.1. Quantitative Pathology Imaging System

            8.6.1.2. Immunofluorescence Slide Scanner

            8.6.1.3. Multispectral Imaging Systems

            8.6.1.4. Toponome imaging System

        8.6.2. Software

        8.6.3. Services

            8.6.3.1. Installation & Integration Services

            8.6.3.2. Maintenance Service

    8.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        8.7.1. Immunohistochemistry (IHC) Assay

        8.7.2. Fluorescent In Situ Hybridization (FISH) Assay

        8.7.3. Tissue Microarray (TMA) Assay

    8.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        8.8.1. Immunohistochemistry (IHC) Assay

        8.8.2. Fluorescent In Situ Hybridization (FISH) Assay

        8.8.3. Tissue Microarray (TMA) Assay

    8.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        8.9.1. Research

        8.9.2. Clinical Diagnostics

    8.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        8.10.1. Research

        8.10.2. Clinical Diagnostics

    8.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        8.11.1. Translational Laboratories

        8.11.2. Biopharmaceutical Companies

        8.11.3. Academic Institutes

    8.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        8.12.1. Translational Laboratories

        8.12.2. Biopharmaceutical Companies

        8.12.3. Academic Institutes

    8.13. Drivers and Restraints: Impact Analysis

    8.14. Market Attractiveness Analysis

        8.14.1. By Country

        8.14.2. By Component Type

        8.14.3. By Imaging Technique

        8.14.4. Application

        8.14.5. End User

    8.15. Key Representative Market Presence (Intensity Map)

9. Japan Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        9.2.1. Instruments

            9.2.1.1. Quantitative Pathology Imaging System

            9.2.1.2. Immunofluorescence Slide Scanner

            9.2.1.3. Multispectral Imaging Systems

            9.2.1.4. Toponome imaging System

        9.2.2. Software

        9.2.3. Services

            9.2.3.1. Installation & Integration Services

            9.2.3.2. Maintenance Service

    9.3. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        9.3.1. Instruments

            9.3.1.1. Quantitative Pathology Imaging System

            9.3.1.2. Immunofluorescence Slide Scanner

            9.3.1.3. Multispectral Imaging Systems

            9.3.1.4. Toponome imaging System

        9.3.2. Software

        9.3.3. Services

            9.3.3.1. Installation & Integration Services

            9.3.3.2. Maintenance Service

    9.4. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        9.4.1. Immunohistochemistry (IHC) Assay

        9.4.2. Fluorescent In Situ Hybridization (FISH) Assay

        9.4.3. Tissue Microarray (TMA) Assay

    9.5. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        9.5.1. Immunohistochemistry (IHC) Assay

        9.5.2. Fluorescent In Situ Hybridization (FISH) Assay

        9.5.3. Tissue Microarray (TMA) Assay

    9.6. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        9.6.1. Research

        9.6.2. Clinical Diagnostics

    9.7. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        9.7.1. Research

        9.7.2. Clinical Diagnostics

    9.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        9.8.1. Translational Laboratories

        9.8.2. Biopharmaceutical Companies

        9.8.3. Academic Institutes

    9.9. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        9.9.1. Translational Laboratories

        9.9.2. Biopharmaceutical Companies

        9.9.3. Academic Institutes

    9.10. Market Attractiveness Analysis

        9.10.1. By Component Type

        9.10.2. By Imaging Technique

        9.10.3. Application

        9.10.4. End User

    9.11. Key Representative Market Presence (Intensity Map)

10. Middle East and Africa Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029

    10.1. Introduction

    10.2. Regional Market Dynamics

        10.2.1. Drivers

        10.2.2. Restraints

        10.2.3. Trends

    10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2021

        10.3.1. GCC Countries

        10.3.2. South Africa

        10.3.3. Rest of MEA

    10.4. Market Size (US$ Mn) Forecast By Country, 2022-2029

        10.4.1. GCC Countries

        10.4.2. South Africa

        10.4.3. Rest of MEA

    10.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        10.5.1. Instruments

            10.5.1.1. Quantitative Pathology Imaging System

            10.5.1.2. Immunofluorescence Slide Scanner

            10.5.1.3. Multispectral Imaging Systems

            10.5.1.4. Toponome imaging System

        10.5.2. Software

        10.5.3. Services

            10.5.3.1. Installation & Integration Services

            10.5.3.2. Maintenance Service

    10.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2022–2029

        10.6.1. Instruments

            10.6.1.1. Quantitative Pathology Imaging System

            10.6.1.2. Immunofluorescence Slide Scanner

            10.6.1.3. Multispectral Imaging Systems

            10.6.1.4. Toponome imaging System

        10.6.2. Software

        10.6.3. Services

            10.6.3.1. Installation & Integration Services

            10.6.3.2. Maintenance Service

    10.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2021

        10.7.1. Immunohistochemistry (IHC) Assay

        10.7.2. Fluorescent In Situ Hybridization (FISH) Assay

        10.7.3. Tissue Microarray (TMA) Assay

    10.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        10.8.1. Immunohistochemistry (IHC) Assay

        10.8.2. Fluorescent In Situ Hybridization (FISH) Assay

        10.8.3. Tissue Microarray (TMA) Assay

    10.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        10.9.1. Research

        10.9.2. Clinical Diagnostics

    10.10. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        10.10.1. Research

        10.10.2. Clinical Diagnostics

    10.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2021

        10.11.1. Translational Laboratories

        10.11.2. Biopharmaceutical Companies

        10.11.3. Academic Institutes

    10.12. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        10.12.1. Translational Laboratories

        10.12.2. Biopharmaceutical Companies

        10.12.3. Academic Institutes

    10.13. Drivers and Restraints: Impact Analysis

    10.14. Market Attractiveness Analysis

        10.14.1. By Country

        10.14.2. By Component Type

        10.14.3. By Imaging Technique

        10.14.4. Application

        10.14.5. End User

    10.15. Key Representative Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape

    13.1. Competition Dashboard

    13.2. Company Share Analysis

    13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments and SWOT Analysis)

        13.3.1. Perkin Elmer, Inc.

        13.3.2. Bio-Rad Laboratories Inc.

        13.3.3. Thermo Fisher Scientific, Inc.

        13.3.4. Abcam plc.

        13.3.5. Merck KGaA

        13.3.6. Illumina Inc.

        13.3.7. Leica Biosystems Nussloch GmbH

        13.3.8. Ventana Medical Systems, Inc.

        13.3.9. Aushon BioSystems Ltd.

        13.3.10. MicroConstants, Inc.

        13.3.11. ToposNomos Ltd.

14. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Region

    14.1. Introduction / Key Findings

    14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2021

        14.2.1. North America

        14.2.2. Latin America

        14.2.3. Western Europe

        14.2.4. Eastern Europe

        14.2.5. Asia Pacific Excluding Japan

        14.2.6. Japan

        14.2.7. Middle East and Africa

    14.3. Market Size (US$ Mn) Forecast By Region, 2022–2029

        14.3.1. North America

        14.3.2. Latin America

        14.3.3. Western Europe

        14.3.4. Eastern Europe

        14.3.5. Asia Pacific Excluding Japan

        14.3.6. Japan

        14.3.7. Middle East and Africa

    14.4. Market Attractiveness Analysis By Region

15. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Component Type

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2021

        15.2.1. Instruments

            15.2.1.1. Quantitative Pathology Imaging System

            15.2.1.2. Immunofluorescence Slide Scanner

            15.2.1.3. Multispectral Imaging Systems

            15.2.1.4. Toponome imaging System

        15.2.2. Software

        15.2.3. Services

            15.2.3.1. Installation & Integration Services

        15.2.4. Maintenance Service

    15.3. Market Size (US$ Mn) and Volume Forecast By Component Type,2022–2029

        15.3.1. Instruments

            15.3.1.1. Quantitative Pathology Imaging System

            15.3.1.2. Immunofluorescence Slide Scanner

            15.3.1.3. Multispectral Imaging Systems

            15.3.1.4. Toponome imaging System

        15.3.2. Software

        15.3.3. Services

            15.3.3.1. Installation & Integration Services

        15.3.4. Maintenance Service

    15.4. Market Attractiveness Analysis by Component Type

16. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis, by Imaging Technique, 2012-2021

        16.2.1. Immunohistochemistry (IHC) Assay

        16.2.2. Fluorescent In Situ Hybridization (FISH) Assay

        16.2.3. Tissue Microarray (TMA) Assay

    16.3. Market Size (US$ Mn) Forecast, by Imaging Technique, 2022–2029

        16.3.1. Immunohistochemistry (IHC) Assay

        16.3.2. Fluorescent In Situ Hybridization (FISH) Assay

        16.3.3. Tissue Microarray (TMA) Assay

    16.4. Market Attractiveness Analysis by Imaging Technique 

17. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By Application

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis, by Application, 2012-2021

        17.2.1. Research

        17.2.2. Clinical Diagnostics

    17.3. Market Size (US$ Mn) Forecast, by Application, 2022–2029

        17.3.1. Research

        17.3.2. Clinical Diagnostics

    17.4. Market Attractiveness Analysis by Application

18. Global Multiplex Biomarker Imaging Market Analysis 2012-2021 and Forecast 2022–2029, By End User

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis, by End User, 2012-2021

        18.2.1. Translational Laboratories

        18.2.2. Biopharmaceutical Companies

        18.2.3. Academic Institutes

    18.3. Market Size (US$ Mn) Forecast, by End User, 2022–2029

        18.3.1. Translational Laboratories

        18.3.2. Biopharmaceutical Companies

        18.3.3. Academic Institutes

    18.4. Market Attractiveness Analysis by End User

19. Global Market Analysis 2012-2021 and Forecast 2022–2029

    19.1. Market Size and Y-o-Y Growth

    19.2. Absolute $ Opportunity

20. Assumptions and Acronyms Used

21. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: CPT Codes for Digital Pathology

Table 02: DPA Regulatory FDA 510(k) List

Table 03: DPA Regulatory FDA 510(k) List

Table 04: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 05: North America Multiplex Biomarker Imaging Market Volume Analysis 2012-2021 and Forecast 2022–2029, By Component Type

Table 06: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 07: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 08: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 09: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 10: North America Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 11: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 12: Latin America Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 13: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 14: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 15: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 16: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 17: Latin America Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 18: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 19: Western Europe Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 20: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 21: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 22: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 23: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 24: Western Europe Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 25: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 26: Eastern Europe Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 27: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 28: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 29: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 30: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 31: Eastern Europe Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 32: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 33: APEJ Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 34: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 35: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 36: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 37: APEJ Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 38: APEJ Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 39: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 40: Japan Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 41: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 42: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 43: Japan Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 44: Japan Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 45: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 46: MEA Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 47: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 48: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 49: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Table 50: MEA Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Country

Table 51: MEA Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)

Table 52:  Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Region

Table 53: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 54: Global Multiplex Biomarker Imaging Market Volume Analysis-2012-2021 and Forecast 2022–2029, By Component Type

Table 55: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Imaging Technique

Table 56: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By Application

Table 57: Global Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012-2021 and Forecast 2022–2029, By End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

 

Figure 01: U.S FDA Regulatory Approval for Medical Devices

Figure 02: Europe Regulatory Approval for Medical Devices

Figure 03: Japan Regulatory Approval for Medical Devices

Figure 04: North America Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 06: North America Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 05: North America Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 07: North America Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 08: North America Multiplex Biomarker Imaging Market Value Share by Country (2022)

Figure 09: North America Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 10: North America Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 11: U.S. Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 12: U.S. Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 13: Canada Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 14: Canada Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 15: North America Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 16: North America Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 17: North America Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 18: North America Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 19: North America Multiplex Biomarker Imaging Market Attractive Analysis by Country, 2022–2029

Figure 20: North America - Drivers & Restrains Impact Analysis

Figure 21: Latin America Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 23: Latin America Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 22: Latin America Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 24: Latin America Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 25: Latin America Multiplex Biomarker Imaging Market Value Share by Country (2022)

Figure 26: Latin America Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 27: Latin America Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 28: Brazil Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 29: Brazil Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 30: Mexico Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 31: Mexico Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 32: Argentina Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 33: Argentina Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 34: Rest of Latin America Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 35: Rest of Latin America Multiplex Biomarker Imaging Market Forecast, 2012 - 2021

Figure 36: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 37: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 38: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 39: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 40: Latin America Multiplex Biomarker Imaging Market Attractive Analysis by Country, 2022–2029

Figure 41: Latin America - Drivers & Restraint Impact Analysis

Figure 42: Western Europe Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 44: Western Europe Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 43: Western Europe Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 45: Western Europe Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 46: Western Europe Multiplex Biomarker Imaging Market Value Share by Country (2022)

Figure 47: Western Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 48: Western Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 49: U.K. Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 50: U.K. Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 51: Germany Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 52: Germany Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 53: France Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 54: France Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 55: Italy Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 56: Italy Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 57: Spain Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 58: Spain Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 59: Nordics Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 60: Nordics Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 61: Benelux Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 62: Benelux Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 63: Rest of Western Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 64: Rest of Western Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 65: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 66: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 67: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 68: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 69: Western Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 70: Europe - Drivers & Restraint Impact Analysis

Figure 70: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 72: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 71: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 73: Eastern Europe Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 74: Eastern Europe Multiplex Biomarker Imaging Market Value Share by Country (2022)

Figure 75: Eastern Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 76: Eastern Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 77: Russia Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 78: Russia Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 79: Poland Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 80: Poland Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 81: Rest of Eastern Europe Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 82: Rest of Eastern Europe Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 83: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 84: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 85: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 86: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 87: Eastern Europe Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 88: APEJ Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 90: APEJ Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 89: APEJ Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 91: APEJ Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 92: APEJ Multiplex Biomarker Imaging Market Value Share by Country (2022)

Figure 93: APEJ Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 94: APEJ Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 95: China Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 96: China Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 97: India Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 98: India Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 99: Australia and NZ Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 100: Australia and NZ Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 101: ASEAN Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 102: ASEAN Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 103: Rest of APEJ Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 104: Rest of APEJ Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 105: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 106: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 107: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 108: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 109: APEJ Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 110: APAC - Drivers & Restraint Impact Analysis

Figure 111: Japan Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 113: Japan Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 112: Japan Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 114: Japan Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 115: Japan Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 116: Japan Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 117: Japan Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 118: Japan Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 119: Japan Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 120: Japan Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 121: MEA Multiplex Biomarker Imaging Market Value Share by Component Type (2022)

Figure 123: MEA Multiplex Biomarker Imaging Market Value Share by Application (2022)

Figure 122: MEA Multiplex Biomarker Imaging Market Value Share by Imaging Technique (2022)

Figure 124: MEA Multiplex Biomarker Imaging Market Value Share by End User (2022)

Figure 125: MEA Multiplex Biomarker Imaging Market Value Share by Country (2022)

Figure 126: MEA Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 127: MEA Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 128: South Africa Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 129: South Africa Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 130: GCC Countries Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 131: GCC Countries Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 132: Rest of MEA Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 133: Rest of MEA Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 134: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 135: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Technique, 2022–2029

Figure 136: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 137: MEA Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 138: MEA Multiplex Biomarker Imaging Market Attractive Analysis by Component Type, 2022–2029

Figure 139: MEA Drivers & Restraint Impact Analysis

Figure 140: Global Multiplex Biomarker Imaging Market Share Analysis

Figure 141: Global Multiplex Biomarker Imaging Market Attractive Analysis by Region, 2022–2029

Figure 142: Global Multiplex Biomarker Imaging Market Attractive Analysis by Component, 2022–2029

Figure 143: Global Multiplex Biomarker Imaging Market Attractive Analysis by Imaging Techniques, 2022–2029

Figure 144: Global Multiplex Biomarker Imaging Market Attractive Analysis by Application, 2022–2029

Figure 145: Global Multiplex Biomarker Imaging Market Attractive Analysis by End User, 2022–2029

Figure 146: Global Multiplex Biomarker Imaging Historical Market Analysis 2012 - 2021

Figure 147: Global Multiplex Biomarker Imaging Market Forecast, 2022 - 2029

Figure 148: Global Multiplex Biomarker Imaging Market Absolute $ Opportunity, 2012 - 2021

Figure 149: Global Multiplex Biomarker Imaging Market Absolute $ Opportunity, 2022 – 2029

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Veterinary Molecular Diagnostics Market

Published : December 2021

Healthcare

PD-L1 Biomarker Testing Market

Published : October 2020

Healthcare

Human Identification Market

Published : November 2019

Healthcare

Renal Biomarker Market

Published : November 2016

Google translate

Multiplex Biomarker Imaging Market